Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2023 Annual General Meeting.

Outcome of Innate Pharma's 2023 Annual General Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2023. “Our strong cash position was further bolstered during the first quarter of 2023 as we signed a license agreement with Takeda for antibody drug conjugates (ADC) using a panel of selected Innate antibodies, with a primary focus in Celiac disease. This agreement demonstrates our ability to expa.

Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Prod.

Innate Pharma Announces Conference Call and Webcast for Q1 Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today three abstracts including Innate's product candidates have been accepted for the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One abstract for SAR'579, currently developed by Sanofi, has been selected for oral presentation. SAR'579 is a potential first-in-class NKp46/CD16-based NK cell engager targe.

Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to a new At-The-Market (“ATM”) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75 million of American Depositary Shares (“ADS”), each ADS representing one ordinary share o.

Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 10:30 a.m. CEST on May 12, 2023 in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Annual General Meeting will be broadcasted live. The Notice of Meeting of this AGM was published on April 7, 2023 in the French legal bulletin.

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2022 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2022 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 6, 2023. It can be downloaded (in French) on the Company's website and on the AMF's website.

Innate Pharma Files Its 2022 Universal Registration Document (Document d'enregistrement universel) and 2022 Annual Report on Form 20-F

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

Innate Pharma S.A. (NASDAQ:IPHA ) Q4 2022 Earnings Conference Call March 23, 2023 9:00 AM ET Company Participants Henry Wheeler - Head, Investor Relations Mondher Mahjoubi - Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vice President-Business Development and Product Portfolio Strategy Frederic Lombard - Senior Vice President, Chief Financial Officer Conference Call Participants Carly Kenselaar - Citigroup Daina Graybosch - SVB Securities Arthur He - H.C.

Innate Pharma S.A. (IPHA) Q4 2022 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results1 for the year ending December 31, 2022. The consolidated financial statements are attached to this press release. “In 2022 we made important progress in our pipeline, both on our clinical and preclinical projects as well as maintaining a strong financial position.

Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022.

Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) has learned that Silicon Valley Bank has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. None of Innate Pharma's cash and cash equivalents are held through Silicon Valley Bank and none of its investment portfolio has exposure to Silicon Valley Bank.

Innate Pharma Provides Update on Silicon Valley Bank Exposure

MARSEILLE, France--( BUSINESS WIRE )--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi. The licensing agreement is now effective.

Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers

MARSEILLE, France--( BUSINESS WIRE )--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. The studies were conducted by Innate and Sanofi and published in Nature Biotechnology on January 12, 2023.

Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

AGM Group Holdings Inc - Ordinary Shares - Class A

Assembly Biosciences

Ensysce Biosciences

LianBio

Soleno Therapeutics

Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 6 To Watch With Big News Today

Sanofi

Shares of Innate Pharma SA ADR [S: ipha] rallied 35.2% in premarket trading on Monday after the company said Sanofi SNY, -0.38% licensed its natural killer (NK) cell engager program as part of an already established collaboration between the two companies. "We are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy," Valeria Fantin, Sanofi's global head of oncology research, said in a news release.

Innate, Sanofi ink licensing deal for NK cells

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

MARSEILLE, France--( BUSINESS WIRE )--Regulatory News:

Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

Innate Pharma S.A. (NASDAQ:IPHA ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Henry Wheeler – Head-Investor Relations Mondher Mahjoubi – Chief Executive Officer Joyson Karakunnel – Executive Vice President and Chief Medical Officer Yannis Morel – Executive Vice President-Business Development and Product Portfolio Strategy Conference Call Participants Yigal Nochomovitz – Citigroup Daina Graybosch – SVB Securities Swayampakula Ramakanth – HCW Operator Hello, and thank you for standing by.

Innate Pharma S.A. (IPHA) Q3 2022 Earnings Call Transcript

Innate Pharma Reports Third Quarter Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for third quarter 2022 business update

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the 64th ASH (American Society Hematology) Annual Meeting taking place from December 10-13, 2022, in New Orleans, Louisiana.

Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma 2023 financial calendar

News for Innate Pharma SA Stock (IPHA)